Ichangobva Kusvika 4-Biphenylcarboxylic Acid (92-92-2)

Nehutongi hwedu hwakatanhamara, kugona kwehunyanzvi hwekuita uye kusimba kwemhando yepamusoro yekubata maitiro, tinoenderera mberi nekupa vatengi vedu mhando yakanaka yakavimbika, mitengo yekutengesa inonzwisisika uye masevhisi akanaka.Isu tinovavarira kuve mumwe wevabatsiri vako vane mutoro uye kuwana kugutsikana kwako kweIchangobva Kusvika 4-Biphenylcarboxylic Acid (92-92-2), Musimboti wesangano redu kugara uchipa zvemhando yepamusoro zvekutengesa, sevhisi yehunyanzvi, uye kutaurirana kwechokwadi. .Gamuchirai shamwari dzese kuti dziise muyedzo wekuita mubatanidzwa wenguva refu webhizinesi.
Nehutongi hwedu hwakatanhamara, kugona kwehunyanzvi hwekuita uye kusimba kwemhando yepamusoro yekubata maitiro, tinoenderera mberi nekupa vatengi vedu mhando yakanaka yakavimbika, mitengo yekutengesa inonzwisisika uye masevhisi akanaka.Isu tinovavarira kuve mumwe wevabatsiri vako vane mutoro uye kuwana kugutsikana kwakoChina Organic Synthesis Intermediates, Zvitengeswa zvedu zvinonyanya kutumirwa kuSoutheast Asia, Middle East, North America neEurope.Hunhu hwedu hunovimbiswa zvechokwadi.Kana iwe uchifarira chimwe chezvinhu zvedu kana uchida kukurukura tsika yekuraira, ita shuwa kuti unonzwa wakasununguka kutibata nesu.Tiri kutarisira kuumba hukama hwebhizinesi hwakabudirira nevatengi vatsva pasi rese munguva pfupi iri kutevera.

2'-hydroxy-3'-nitro-3-biphenylcarboxylic acid inoshandiswa sepakati peEltrombopag.
Eltrombopag, yakagadziridzwa naGlaxoSmithKline (GSK) kuUK uye yakazogadziriswa pamwe chete neNovartis kuSwitzerland, ndiyo yekutanga uye yakatenderwa chete mamorekuru madiki asiri peptide TPO receptor agonist munyika.Eltrombopag yakabvumidzwa neUS FDA muna 2008 kurapwa kweidiopathic thrombocytopenic purpura (ITP), uye muna 2014 kurapwa kweaplastic anemia (AA).Ndiwo zvakare mushonga wekutanga wakabvumidzwa neUS FDA kurapwa kweAA mumakore makumi matatu apfuura.
Muna Zvita 2012, US FDA yakabvumidza Eltrombopag kurapwa kwethrombocytopenia muvarwere vane chisingaperi hepatitis C (CHC), kuitira kuti varwere veHepatitis C vane hurombo husina kunaka nekuda kwekuderera kweplatelet count vanogona kutanga nekuchengetedza interferon based standard therapy yezvirwere zvechiropa.Musi waFebruary 3, 2014, GlaxoSmithKline yakazivisa kuti FDA yakapa mukana wekurapa mushonga weEltrombopag kurapwa kwehemopenia muvarwere vane yakanyanya chemicalbook aplastic anemia (SAA) vasina kupindura zvizere kune immunotherapy.Musi waNyamavhuvhu 24, 2015, US FDA yakabvumidza Eltrombopag kurapwa kwethrombocytopenia muvakuru nevana vane makore 1 uye kupfuura vane chronic immune thrombocytopenia (ITP) vasina mhinduro yakakwana kune corticosteroids, immunoglobulins kana splenectomy.Musi waJanuary4, 2018, Eltrombopag yakabvumidzwa kunyorwa muChina kurapwa kwekutanga immune thrombocytopenia (ITP).

Nehutongi hwedu hwakatanhamara, kugona kwehunyanzvi hwekuita uye kusimba kwemhando yepamusoro yekubata maitiro, tinoenderera mberi nekupa vatengi vedu mhando yakanaka yakavimbika, mitengo yekutengesa inonzwisisika uye masevhisi akanaka.Isu tinovavarira kuve mumwe wevabatsiri vako vane mutoro uye kuwana kugutsikana kwako kweIchangobva Kusvika 4-Biphenylcarboxylic Acid (92-92-2), Musimboti wesangano redu kugara uchipa zvemhando yepamusoro zvekutengesa, sevhisi yehunyanzvi, uye kutaurirana kwechokwadi. .Gamuchirai shamwari dzese kuti dziise muyedzo wekuita mubatanidzwa wenguva refu webhizinesi.
Kusvirwa KutsvaChina Organic Synthesis Intermediates, Zvitengeswa zvedu zvinonyanya kutumirwa kuSoutheast Asia, Middle East, North America neEurope.Hunhu hwedu hunovimbiswa zvechokwadi.Kana iwe uchifarira chimwe chezvinhu zvedu kana uchida kukurukura tsika yekuraira, ita shuwa kuti unonzwa wakasununguka kutibata nesu.Tiri kutarisira kuumba hukama hwebhizinesi hwakabudirira nevatengi vatsva pasi rese munguva pfupi iri kutevera.